Mid Atlantic Bio Angels

New View Surgical, Inc. is a Boston-based medical device company that specializes in the development and commercialization of the VisionPort technology, a novel surgical imaging and access system designed for minimally invasive surgery. Founded in 2009, the company has created a proprietary system that integrates four essential devices—a laparoscope, camera, light source, and access port—into a single, easy-to-use, and disposable unit. This innovation aims to provide surgeons with enhanced control over visualization and instrumentation during procedures, addressing various unmet needs within the surgical market. The leadership team comprises experienced professionals in medical device innovation and commercialization, dedicated to delivering impactful solutions that offer both clinical and economic benefits to operating rooms worldwide.

Astrocyte Pharmaceuticals Inc. is a privately held drug development company based in Cambridge, Massachusetts, focused on creating neuroprotection therapies for various brain injuries, including traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer’s disease. Incorporated in 2014, the company is advancing its lead product, AST-004, a novel small molecule designed for acute administration. This therapy aims to protect and repair damaged neurons by selectively stimulating astrocytes, a type of brain cell crucial for neuronal health. Astrocyte Pharmaceuticals is dedicated to demonstrating the neuroprotective benefits of its approach and improving outcomes for patients suffering from brain injuries.

New View Surgical, Inc. is a Boston-based medical device company that specializes in the development and commercialization of the VisionPort technology, a novel surgical imaging and access system designed for minimally invasive surgery. Founded in 2009, the company has created a proprietary system that integrates four essential devices—a laparoscope, camera, light source, and access port—into a single, easy-to-use, and disposable unit. This innovation aims to provide surgeons with enhanced control over visualization and instrumentation during procedures, addressing various unmet needs within the surgical market. The leadership team comprises experienced professionals in medical device innovation and commercialization, dedicated to delivering impactful solutions that offer both clinical and economic benefits to operating rooms worldwide.

Healionics Corporation, based in Seattle, Washington, specializes in the development and manufacture of synthetic biomaterials and implantable medical devices aimed at improving healthcare for kidney failure patients. The company has created the STARport HD, an implantable device that enables needle-free bloodstream access for hemodialysis, and the STARgraft, a synthetic vascular graft designed to maintain long-term blood flow without the complications associated with traditional grafts. Healionics' innovative approach addresses critical challenges in dialysis treatment, such as the high costs and health risks associated with current vascular access methods. Their technology promises to enhance patient outcomes by reducing the need for costly interventions and minimizing complications like infection and scarring. With a robust patent portfolio and successful results from animal studies, Healionics is poised to begin human trials and further develop its product line, which includes additional applications for its STAR biomaterial in various medical devices.

Virion Therapeutics, LLC, a biotechnology company, develops immune-based treatments for virally-associated cancers and chronic viral infections. It offers ChiVax and ChiVax-gD vaccines to induce potent and sustained T cell-mediated immune responses against transformed and infected cells. Virion Therapeutics, LLC was incorporated in 2018 and is based in Newark, Delaware.

FEMSelect Inc. specializes in designing and developing surgical systems and devices for pelvic floor ligament fixation, focusing on women's health. The company is known for its innovative EnPlace system, a minimally invasive and mesh-free solution for treating pelvic organ prolapse (POP). This patented technology allows for precise guidance and deployment of an anchor unit that stabilizes the pelvic floor ligament through a vaginal approach, significantly enhancing patient recovery and comfort. The procedure typically takes about 30 minutes and does not require overnight hospital stays or result in visible scarring. Founded in 2012, FEMSelect operates from its headquarters in Newark, Delaware.

Elysium Therapeutics is a healthcare company established in 2013 and located in Danville, California. The company specializes in biotechnology and has developed innovative opioid pain relievers aimed at reducing the risks associated with oral misuse, abuse, and fatal overdose. Elysium Therapeutics' opioid medications are designed to automatically regulate opioid levels in the bloodstream, preventing them from exceeding safe limits. This approach not only minimizes the potential for addiction and adverse side effects but also enhances the ability of medical practitioners to manage pain effectively in patients requiring opioid-based treatments.

A biotech company, engages in developing monoclonal antibodies to treat fibrotic and remodeling diseases. The company was founded in 2012 and is headquartered in Bryn Mawr, Pennsylvania .

PainQx is a diagnostic/software company that has developed a next generation approach to objectively measure pain in humans. The PainQx platform achieves this by assessing neural activity from a patient’s brain and processing and decoding the data through proprietary algorithms. The output is a scaled pain and neurological side effects biomarker that is directly correlated to a patient’s pain state. The PainQx system is currently being used as a clinical assessment tool by companies using pain as a primary or secondary clinical end point to measure their drug’s and/or device’s efficacy.

New View Surgical, Inc. is a Boston-based medical device company that specializes in the development and commercialization of the VisionPort technology, a novel surgical imaging and access system designed for minimally invasive surgery. Founded in 2009, the company has created a proprietary system that integrates four essential devices—a laparoscope, camera, light source, and access port—into a single, easy-to-use, and disposable unit. This innovation aims to provide surgeons with enhanced control over visualization and instrumentation during procedures, addressing various unmet needs within the surgical market. The leadership team comprises experienced professionals in medical device innovation and commercialization, dedicated to delivering impactful solutions that offer both clinical and economic benefits to operating rooms worldwide.

Genome Profiling, LLC is a bioinformatics company specializing in the discovery of novel epigenetic biomarkers to aid in the diagnosis, treatment, and prediction of chronic and life-threatening diseases. Established in 2012 and located in Wayne, Pennsylvania, the company offers GenPro Analytics, a software platform designed for scientists and medical professionals. This platform improves the sensitivity, specificity, and accuracy of disease prediction and monitoring while also being cost-effective. Genome Profiling is notable for its innovative approach, combining a proprietary pre-NGS gDNA preparation kit with advanced NGS data analytics algorithms. This integration allows a single NGS run to generate comprehensive data for both genomic variant analysis and epigenetic research, positioning the company at the forefront of the emerging epigenetic biomarker market.

Forge Life Science is specializing in antivirals engages the cell’s intrinsic immunity to defend against infection. The company's products will address the infectious disease condition as opposed to targeting a specific virus-type. Imagine being prescribed a safe, broad-spectrum antiviral, without the risk of acquired drug-resistance, based on symptom presentation, and prior to diagnostic confirmation of infecting virus-type. Their highly-innovative products are early-stage, yet we bring tangible solutions to solve real clinical challenges and unmet medical needs.

Immunomic Therapeutics, Inc., a clinical-stage biotechnology company, conducts studies nucleic acid immunotherapy platforms for immunotherapy for the treatment of cancer, allergies, and animal health. The company provides UNiversal Intracellular Targeted Expression (UNITE) platform for cancer immunotherapy, allergy, and infectious diseases. It offers LAMP-Vax platform for DNA vaccine for antigen presentation and enhances immune system responses to vaccination. Immunomic Therapeutics, Inc. was founded in 2005 and is based in Rockville, Maryland with an additional office in South Korea.

Cerus Endovascular Ltd specializes in designing and developing interventional neuroradiology devices aimed at the minimally invasive treatment of neurovascular diseases, with a primary focus on intracranial aneurysms. Founded in 2011 and headquartered in Oxford, United Kingdom, with an additional location in Fremont, California, the company has created the e-clipse device, an aneurysm occlusive tool. This device offers a novel alternative to existing treatment methods, including surgical clipping, metal coils, and liquid embolics. Cerus Endovascular's products cater to a variety of aneurysm morphologies and are particularly beneficial for treating hemorrhagic strokes, enabling interventional neuroradiologists to effectively address complex cases in a less invasive manner.